Searchable abstracts of presentations at key conferences in endocrinology

ea0016oc5.6 | Reproduction | ECE2008

Effects of pregnancy on GH/IGF-1 concentrations in acromegalic women

Broussaud Stephanie , Brue Thierry , Chanson Philippe , Cortet-Rudelli Christine , Caron Philippe

In normal woman, placental GH secretion increases during gestation and induces an increase of IGF-1 concentrations. In acromegalic women, increased pituitary GH secretion seems autonomous and IGF-1 increases in late stage of pregnancy related to placental GH. In a cohort of 46 women (mean age 31.7±4.5 years), acromegaly was due to micro (n=7) and macro (n=39) adenomas. Before the beginning of 59 pregnancies, women have been treated by transphenoidal surgery ...

ea0090p402 | Pituitary and Neuroendocrinology | ECE2023

Treatment Patterns in Acromegaly: Analysis of Real-World US Insurance Claims from the MarketScan® Database

Brue Thierry , Fleseriu Maria , Barkan Ariel , Duquesne Edouard , Houchard Aude , del Pilar Schneider Maria , Ribeiro-Oliveira Antonio , Melmed Shlomo K.

Background: Medical treatment for acromegaly (characterized by excess growth hormone [GH] production) includes somatostatin receptor ligands (SRLs), dopamine agonists (DAs), and GH receptor antagonists (GHRAs). However, recent real-world United States (US) treatment evaluations are few. We present treatment patterns for patients receiving medications for acromegaly (1/1/2010–31/7/2022).Methods: De-identified data were extracted from MarketScan&...

ea0037gp.19.09 | Pituitary–Acromegaly | ECE2015

Management of pasireotide-induced hyperglycaemia with proactive monitoring and early intervention: key learnings from the phase III, 24-week PAOLA study

Gadelha Monica R , Brue Thierry , Fleseriu Maria , Shimon Ilan , Resendiz Karina Hermosillo , Kandra Albert , Pedroncelli Alberto M , Colao AnnaMaria

Introduction: In PAOLA study, pasireotide showed superior efficacy over continued treatment with octreotide/lanreotide in patients with inadequately-controlled acromegaly; 64% of patients receiving pasireotide long-acting release (LAR) reported hyperglycaemia-related adverse events. Pasireotide has been shown to inhibit insulin secretion. The aim of this exploratory analysis was to investigate the effect of timing of antidiabetic medication (ADM) intervention on the fasting pl...

ea0035p905 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Effect of pasireotide on GH, IGF1, IGFBP2, IGFBP3, HbA1C and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA)

Schmid Herbert , Brue Thierry , Colao Annamaria , Gadelha Monica , Shimon Ilan , Kapur Karen , D'Amato Lisa , Pedroncelli Alberto , Fleseriu Maria

Background: The PAOLA study assessed the efficacy/safety of pasireotide LAR vs continued treatment with octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly. An exploratory objective was to measure changes in various associated biomarkers, including IGF1 and IGFBP2 (released from white fat cells and known to prevent insulin resistance), glucose and HbA1c.Methods: Adult patients (GH >2.5 μg/l and IGF1 >1.3&#21...

ea0020p602 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Pituitary insufficiency with a HESX1 mutation: a new case

Lecomte Pierre , Saveanu Alexandranu , Barlier-Setti Anne , Brue Thierry , Lecomte Claire , Barrande Gaelle , Chabrolle Christine , Pierre Peggy

A 14 year-old Turkish boy sought advice for growth retardation. Pituitary insufficiency with GH, TSH, ACTH and gonadotrophin defect was diagnosed and treated. He was born from a consanguineous family and was married at 24. Three years later he consulted wishing to father a child. He was treated with levothyroxine 150 μg, hGH 0,5 mg/day, hydrocortisone 20 mg/day and was switched from testosterone enantate to hCG+FSH. Azoospermia was initially found and oligospermia after t...

ea0073aep844 | Late Breaking | ECE2021

The relative’s viewpoint on acromegaly in remission : A psychosocial dimension of a chronic disease

Fourneaux Rachel , Marie Vermalle , Albarel Frederique , Morange Isabelle , Graillon Thomas , Amodru Vincent , Cuny Thomas , Dufour Henry , Brue Thierry , Castinetti Frederic

Aim of the studyA relative can be an asset in dealing with chronic illnesses such as acromegaly where quality of life is altered even after remission. However, it has been shown that quality of life of caregivers can also be impacted. Our main objective was to explore the consequences of acromegaly in remission in the patient-relative dyad in a matter of quality of life and self-esteem.MethodsIn this French m...

ea0049gp192 | Pituitary &amp; endocrine Tumours | ECE2017

Long-term treatment with pegvisomant (Somavert®): Observations from 2090 acromegaly patients followed in ACROSTUDY

vanderLely Aart Jan , Biller Beverly , Brue Thierry , Buchfelder Michael , Ghigo Ezio , Pan kaijie , Jonsson Peter , Lavenberg Joanne , Strasburger Christian J. , Webb Susan , Camacho-Hubner Cecilia , Hey-Hadavi Judith

Introduction: Pegvisomant (PEGV) is approved for the treatment of acromegaly since 2003. This is the second interim analysis of data from ACROSTUDY, with the majority of patients treated for at least five years (yrs).Methods/design: ACROSTUDY is an international, open-label, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of PEGV. Patients were enrolled in the study on an ongoing basis.<...

ea0041ep876 | Pituitary - Clinical | ECE2016

ACRO-POLIS study: differences of symptoms and comorbidities in 472 acromegalic patients according the sex of patients and sources of clinical data

Caron Philippe , Chanson Philippe , Raverot Gerald , Tabarin Antoine , Cailleux Anne , Delemer Brigitte , Renoult Peggy Pierre , Houchard Aude , Cloitre Pauline , Brue Thierry

Introduction: Acromegaly is characterized by excessive secretion of GH and increased IGF-1 levels caused by benign pituitary adenoma. The ACRO-POLIS study describes symptoms and comorbidities of acromegaly at diagnosis in a large cohort of patients diagnosed between 2009 and 2014 in France.Methodology: Observational, cross-sectional, multicentre study included adult patients with acromegaly diagnosed for less than 5 years. Data were collected retrospecti...

ea0037ep743 | Pituitary: clinical | ECE2015

Symptoms and comorbidities at diagnosis of 472 acromegalic patients diagnosed between 2009 and 2014

Caron Philippe , Brue Thierry , Chanson Philippe , Raverot Gerald , Tabarin Antoine , Cailleux Anne , Delemer Brigitte , Renoult Peggy Pierre , Houchard Aude , Dupuis-Simeon Frederique

Introduction: Acromegaly is characterised by chronic, excessive secretion of GH and increased IGF1 levels caused by benign pituitary adenoma. This study aimed at describing the symptoms and comorbidities of acromegaly at diagnosis, in a large cohort of patients diagnosed between 2009 and 2014.Methods: Observational, cross-sectional, multicentre study conducted in France between September 2013 and June 2014. Adult patients with acromegaly diagnosed for &#...

ea0056gp133 | Female Reproduction | ECE2018

Favorable prognosis of pregnancies in 28 hypopituitary women: Retrospective multicentric study on 39 pregnancies

Melloul Eve , Chabre Olivier , Caron Philippe , Young Jacques , Bry Helene , Raverot Gerald , Chazot Francoise Borson , Brosse Aurelie , Brue Thierry , Castinetti Frederic , Hoffmann Pascale , Villaret Laure

Background: Pregnancy in women with hypopituitarism has been described as presenting high risks of maternal and fetal complications but this is only based on 2 small size series.Objective: To reassess the prognosis of pregnancy in women with hypopituitarism.Methods: Multicentric, observational, retrospective study including 39 pregnancies in 28 women with gonadotropic insufficiency and at least one other pituitary hormone deficienc...